Publications

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, John L. Berk, Thibaud Damy, et al

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Karola S. Jering, Marianna Fontana, Hicham Skali, et al

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

Transthyretin Amyloidosis (ATTR)

Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry

Transthyretin Amyloidosis (ATTR)

Treatment with vutrisiran in individuals with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Future Cardiology

Author(s)

Marianna Fontana, Julian D Gillmore, Ronald M Witteles

Transthyretin Amyloidosis (ATTR)

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B

Journal of the American College of Cardiology

Author(s)

Ronald Witteles, Pablo Garcia-Pavia, Thibaud Damy

Primary Hyperoxaluria Type 1 (PH1)

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial

American Journal of Kidney Diseases

Author(s)

Anne-Laure Sellier-Leclerc, Daniella Magen, Hadas Shasha-Lavsky, et al

Preparation Date
March 2026
Job Code
MB-UK-00029